This was the stock's third consecutive day of losses.
This was the stock's second consecutive day of losses.
Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...
CWA Asset Management Group LLC cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 4th quarter, ...
DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...
BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...
In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...
AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.